无症状和症状前严重急性呼吸系统综合征冠状病毒2型感染的发生和传播潜力:一项活的系统综述和荟萃分析的更新

IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL PLoS Medicine Pub Date : 2022-05-26 eCollection Date: 2022-05-01 DOI:10.1371/journal.pmed.1003987
Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Anthony Hauser, Muhammad Irfanul Alam, Kaspar Meili, Eric A Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William Gildardo Robles-Rodriguez, Shabnam Thapa, Ivan Zhelyazkov, Georgia Salanti, Nicola Low
{"title":"无症状和症状前严重急性呼吸系统综合征冠状病毒2型感染的发生和传播潜力:一项活的系统综述和荟萃分析的更新","authors":"Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Anthony Hauser, Muhammad Irfanul Alam, Kaspar Meili, Eric A Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William Gildardo Robles-Rodriguez, Shabnam Thapa, Ivan Zhelyazkov, Georgia Salanti, Nicola Low","doi":"10.1371/journal.pmed.1003987","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Debate about the level of asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection continues. The amount of evidence is increasing and study designs have changed over time. We updated a living systematic review to address 3 questions: (1) Among people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a population is accounted for by people who are asymptomatic or presymptomatic?</p><p><strong>Methods and findings: </strong>The protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched PubMed, Embase, bioRxiv, and medRxiv, aggregated in a database of SARS-CoV-2 literature, most recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented symptom status at the beginning and end of follow-up, or mathematical modelling studies were included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses were done using random effects models. Review question (1): We included 130 studies. Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall (interquartile range (IQR) 14% to 50%, prediction interval 2% to 90%), or in 84 studies based on screening of defined populations (IQR 20% to 65%, prediction interval 4% to 94%). In 46 studies based on contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% confidence interval (CI) 15% to 25%, prediction interval 2% to 70%). (2) The secondary attack rate in contacts of people with asymptomatic infection compared with symptomatic infection was 0.32 (95% CI 0.16 to 0.64, prediction interval 0.11 to 0.95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2 transmission from presymptomatic individuals was higher than from asymptomatic individuals. Limitations of the evidence include high heterogeneity and high risks of selection and information bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated.</p><p><strong>Conclusions: </strong>Based on studies published up to July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. Summary estimates from meta-analysis may be misleading when variability between studies is extreme and prediction intervals should be presented. Future studies should determine the asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2.</p><p><strong>Review protocol: </strong>Open Science Framework (https://osf.io/9ewys/).</p>","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":10.5000,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135333/pdf/","citationCount":"0","resultStr":"{\"title\":\"Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis.\",\"authors\":\"Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Anthony Hauser, Muhammad Irfanul Alam, Kaspar Meili, Eric A Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William Gildardo Robles-Rodriguez, Shabnam Thapa, Ivan Zhelyazkov, Georgia Salanti, Nicola Low\",\"doi\":\"10.1371/journal.pmed.1003987\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Debate about the level of asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection continues. The amount of evidence is increasing and study designs have changed over time. We updated a living systematic review to address 3 questions: (1) Among people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a population is accounted for by people who are asymptomatic or presymptomatic?</p><p><strong>Methods and findings: </strong>The protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched PubMed, Embase, bioRxiv, and medRxiv, aggregated in a database of SARS-CoV-2 literature, most recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented symptom status at the beginning and end of follow-up, or mathematical modelling studies were included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses were done using random effects models. Review question (1): We included 130 studies. Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall (interquartile range (IQR) 14% to 50%, prediction interval 2% to 90%), or in 84 studies based on screening of defined populations (IQR 20% to 65%, prediction interval 4% to 94%). In 46 studies based on contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% confidence interval (CI) 15% to 25%, prediction interval 2% to 70%). (2) The secondary attack rate in contacts of people with asymptomatic infection compared with symptomatic infection was 0.32 (95% CI 0.16 to 0.64, prediction interval 0.11 to 0.95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2 transmission from presymptomatic individuals was higher than from asymptomatic individuals. Limitations of the evidence include high heterogeneity and high risks of selection and information bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated.</p><p><strong>Conclusions: </strong>Based on studies published up to July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. Summary estimates from meta-analysis may be misleading when variability between studies is extreme and prediction intervals should be presented. Future studies should determine the asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2.</p><p><strong>Review protocol: </strong>Open Science Framework (https://osf.io/9ewys/).</p>\",\"PeriodicalId\":20368,\"journal\":{\"name\":\"PLoS Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":10.5000,\"publicationDate\":\"2022-05-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135333/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PLoS Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1371/journal.pmed.1003987\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/5/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1371/journal.pmed.1003987","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景关于无症状严重急性呼吸系统综合征冠状病毒2型感染水平的争论仍在继续。随着时间的推移,证据的数量正在增加,研究设计也发生了变化。我们更新了一项实时系统综述,以解决3个问题:(1)在感染严重急性呼吸系统综合征冠状病毒2型的人中,有多大比例的人在感染期间根本没有症状?(2) 与有症状的严重急性呼吸系统综合征冠状病毒2型感染相比,无症状和症状前感染的传染性是什么?(3) 无症状或症状前的人在人群中传播严重急性呼吸系统综合征冠状病毒2型的比例是多少?方法和发现该方案于2020年4月1日首次发布,最后一次更新于2021年6月18日。我们搜索了PubMed、Embase、bioRxiv和medRxiv,这些文献汇总在严重急性呼吸系统综合征冠状病毒2型文献数据库中,最近一次是在2021年7月6日。包括对PCR诊断为严重急性呼吸系统综合征冠状病毒2型的人的研究,这些研究记录了随访开始和结束时的症状状态,或数学建模研究。仅限于已经确诊的人、单身个人或家庭或没有充分随访的研究被排除在外。一名评审员提取了数据,第二名评审员验证了提取结果,通过讨论或第三名评审员解决了分歧。实证研究中的偏倚风险采用定制清单进行评估,建模研究采用公布的清单进行评估。所有的数据合成都是使用随机效应模型进行的。复习问题(1):我们纳入了130项研究。异质性很高,因此我们没有估计无症状感染者的总体平均比例(四分位间距(IQR)14%至50%,预测区间2%至90%),也没有估计84项基于定义人群筛查的研究(IQR 20%至65%,预测区间4%至94%)。在46项基于接触或疫情调查的研究中,无症状的总比例为19%(95%置信区间(CI)15%至25%,预测区间2%至70%)。(2) 与有症状感染者相比,无症状感染者接触者的二次发病率为0.32(95%CI 0.16-0.64,预测区间0.11-0.95,8项研究)。(3) 在13项符合数据的建模研究中,所有严重急性呼吸系统综合征冠状病毒2型传播中,症状前个体的比例高于无症状个体。证据的局限性包括,在并非旨在测量持续无症状感染的研究中,高异质性、高选择风险和信息偏见,以及关于变异毒株或接种过疫苗的人的信息有限。结论根据截至2021年7月发表的研究,大多数严重急性呼吸系统综合征冠状病毒2型感染者并非持续无症状,无症状感染者的传染性低于有症状感染者。当研究之间的变异性极端且应给出预测区间时,荟萃分析的汇总估计可能会产生误导。未来的研究应确定变异毒株引起的SARS-CoV-2感染的无症状比例,以及接种疫苗或既往感染后具有免疫力的人群。如果没有采用最大限度减少选择和测量偏差的方法进行前瞻性纵向研究,本次活体系统综述中包括的研究类型的进一步更新不太可能对严重急性呼吸系统综合征冠状病毒2型引起的无症状感染的比例提供可靠的汇总估计。审查协议开放科学框架(https://osf.io/9ewys/)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis.

Background: Debate about the level of asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection continues. The amount of evidence is increasing and study designs have changed over time. We updated a living systematic review to address 3 questions: (1) Among people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a population is accounted for by people who are asymptomatic or presymptomatic?

Methods and findings: The protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched PubMed, Embase, bioRxiv, and medRxiv, aggregated in a database of SARS-CoV-2 literature, most recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented symptom status at the beginning and end of follow-up, or mathematical modelling studies were included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses were done using random effects models. Review question (1): We included 130 studies. Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall (interquartile range (IQR) 14% to 50%, prediction interval 2% to 90%), or in 84 studies based on screening of defined populations (IQR 20% to 65%, prediction interval 4% to 94%). In 46 studies based on contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% confidence interval (CI) 15% to 25%, prediction interval 2% to 70%). (2) The secondary attack rate in contacts of people with asymptomatic infection compared with symptomatic infection was 0.32 (95% CI 0.16 to 0.64, prediction interval 0.11 to 0.95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2 transmission from presymptomatic individuals was higher than from asymptomatic individuals. Limitations of the evidence include high heterogeneity and high risks of selection and information bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated.

Conclusions: Based on studies published up to July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. Summary estimates from meta-analysis may be misleading when variability between studies is extreme and prediction intervals should be presented. Future studies should determine the asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2.

Review protocol: Open Science Framework (https://osf.io/9ewys/).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
PLoS Medicine
PLoS Medicine 医学-医学:内科
CiteScore
21.60
自引率
0.60%
发文量
227
审稿时长
3 months
期刊介绍: PLOS Medicine aims to be a leading platform for research and analysis on the global health challenges faced by humanity. The journal covers a wide range of topics, including biomedicine, the environment, society, and politics, that affect the well-being of individuals worldwide. It particularly highlights studies that contribute to clinical practice, health policy, or our understanding of disease mechanisms, with the ultimate goal of improving health outcomes in diverse settings. Unwavering in its commitment to ethical standards, PLOS Medicine ensures integrity in medical publishing. This includes actively managing and transparently disclosing any conflicts of interest during the reporting, peer review, and publication processes. The journal promotes transparency by providing visibility into the review and publication procedures. It also encourages data sharing and the reuse of published work. Author rights are upheld, allowing them to retain copyright. Furthermore, PLOS Medicine strongly supports Open Access publishing, making research articles freely available to all without restrictions, facilitating widespread dissemination of knowledge. The journal does not endorse drug or medical device advertising and refrains from exclusive sales of reprints to avoid conflicts of interest.
期刊最新文献
Impact on beer sales of removing the pint serving size: An A-B-A reversal trial in pubs, bars, and restaurants in England Behavioral risk factors and socioeconomic inequalities in ischemic heart disease mortality in the United States: A causal mediation analysis using record linkage data Is C-reactive protein sufficient to guide antimicrobial therapy for lower respiratory tract infections among children? Results from a stepped-wedge cluster randomized trial in Uganda. The cost-effectiveness of preventing, diagnosing, and treating postpartum haemorrhage: A systematic review of economic evaluations Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1